Invitation to the EBAC-accredited satellite symposium 'Staging therapy in HCM patients with heart failure: New insights', at ESC HF 2024, Lisbon, Portugal.

For more information, please visit the ESC website.

Learning Objectives

Educational Objectives

• Identify patient presentations that provide an entry point to use an HCM-specific therapeutic approach
• Analyze the latest clinical data regarding the use of myosin inhibitors in the treatment of HCM in patients with heart failure
• Discuss the evidence supporting and recommendations of recently published guidelines on HCM

Agenda

Chair: Petar Seferović, MD, PhD - Belgrade, Serbia

09:45 – 09:50  Welcome and introduction - Petar Seferović, MD, PhD - Belgrade, Serbia

09:50 – 10:00  Recognition and diagnosing heart failure in patients with HCM - Aleš Linhart, MD, PhD - Prague, Czech Republic

10:00– 10:10   Optimal pharmacological management of HCM by clinical manifestations - Pablo García-Pavía, MD, PhD - Madrid, Spain

10:10 – 10:20  Evidence-based novel therapies in HCM - Michelle Michels, MD, PhD - Rotterdam, The Netherlands

10:20 – 10:30  Panel discussion and Q&A - All faculty 

CME Accreditation

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC)  for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.

Funding

This symposium is supported by an unrestricted educational grant from Bristol Myers Squibb.